India Pharma Outlook Team | Tuesday, 19 August 2025
Accord BioPharma, Inc., the U.S. arm of Intas Pharmaceuticals, Ltd., has rolled out Imuldosa (ustekinumab-srlf), a match to Stelara (ustekinumab). Sold in ready-to-use syringes and vials, Imuldosa hits the market with the lowest cost for wholesale buyers among other brand ustekinumab copies—giving a 92% cut in price for syringes and a 33% cut for vials.
Approved by the FDA for use just like Stelara, Imuldosa is the third such product from Accord BioPharma, pushing the brand's goal to make more advanced biologic treatments available. The start-up also kicks off with a $0 co-pay plan for those who fit the bill, making sure more people can get it for issues like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
“Cost shouldn't stop you from getting tried-and-true, life-changing care,” said Chrys Kokino, President of Accord US. “Imuldosa shows our drive to not only offer copycat options, but also full answers that really help people.”
Accord BioPharma stresses talking to patients in making help guides, taking pointers from its patient group. The company sees this start as the base of its growing immunity-related product line.
Also Read: Designing Packaging Systems for Regulatory Compliance and Quality
With nearly 50 years of global know-how from Intas Pharmaceuticals, Accord BioPharma is growing its U.S. copies list. It sells Imuldosa, Hercessi (trastuzumab-strf), Camcevi (leuprolide), and runs the whole Udenyca (pegfilgrastim-cbqv) team. They also have more copies waiting for FDA say-so, like one similar to Simponi (golimumab).
Binish Chudgar, Chairman and Managing Director at Intas Pharmacuticals, said, “The start of Imuldosa shows our promise to bring high-value, lower-cost biologics in vital care areas.”
With this move, Accord BioPharma builds up its role as a big name in changing how we get to immunology treatments in the U.S.
